Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Denali Therapeutics Inc's Business Segments
Denali Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Milestone Triggered
Total Revenue
$ 4
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Milestone Triggered0%
- Option Fee Payment0%
- Milestone Payment0%
- Product0%
- Therapeutics0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Milestone Triggered | $ 100 | - |
| Option Fee Payment | $ 10 | - |
| Milestone Payment | $ 10 | - |
2 more segments available
Sign in to unlock the full Denali Therapeutics Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Milestone Triggered0%
- Option Fee Payment0%
- Milestone Payment0%
- Product0%
- Therapeutics0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Milestone Triggered | $ 100 | - |
| Option Fee Payment | $ 10 | - |
| Milestone Payment | $ 10 | - |
2 more segments available
Sign in to unlock the full Denali Therapeutics Inc dataset.
Description of Denali Therapeutics Inc
Denali Therapeutics Inc is a biotechnology company that focuses on discovering and developing treatments for neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.
The company was founded in 2015 by a group of leading scientists and drug developers from Genentech, including Ryan Watts, Alex Schuth, and Marc Tessier-Lavigne.
Denali's approach to drug development is based on the use of proprietary technologies such as the Transport Vehicle platform and the Neuroimmunology platform.
The Transport Vehicle platform is designed to allow large molecules such as antibodies to cross the blood-brain barrier, which is essential for treating neurodegenerative diseases.
The Neuroimmunology platform is focused on developing therapies that modulate the immune system's response to neurodegenerative diseases.
Currently, Denali has several drug candidates in its pipeline that are designed to address the underlying biology of neurodegenerative diseases.
One of the company's lead drug candidates is DNL151, an oral small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), which is a genetically validated target for Parkinson's disease.
Denali also has a collaboration with Sanofi to develop potential treatments for multiple sclerosis and other neuroinflammatory disorders.
The company is headquartered in South San Francisco, California, and has over 400 employees, including scientists, researchers, and drug developers with extensive experience in the biotechnology industry.
Denali has received over $600 million in funding from leading investors such as Fidelity, Flagship Pioneering, and the Alaska Permanent Fund Corporation.
Overall, Denali is focused on developing breakthrough therapies that have the potential to improve the lives of patients with neurodegenerative diseases.
The company was founded in 2015 by a group of leading scientists and drug developers from Genentech, including Ryan Watts, Alex Schuth, and Marc Tessier-Lavigne.
Denali's approach to drug development is based on the use of proprietary technologies such as the Transport Vehicle platform and the Neuroimmunology platform.
The Transport Vehicle platform is designed to allow large molecules such as antibodies to cross the blood-brain barrier, which is essential for treating neurodegenerative diseases.
The Neuroimmunology platform is focused on developing therapies that modulate the immune system's response to neurodegenerative diseases.
Currently, Denali has several drug candidates in its pipeline that are designed to address the underlying biology of neurodegenerative diseases.
One of the company's lead drug candidates is DNL151, an oral small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), which is a genetically validated target for Parkinson's disease.
Denali also has a collaboration with Sanofi to develop potential treatments for multiple sclerosis and other neuroinflammatory disorders.
The company is headquartered in South San Francisco, California, and has over 400 employees, including scientists, researchers, and drug developers with extensive experience in the biotechnology industry.
Denali has received over $600 million in funding from leading investors such as Fidelity, Flagship Pioneering, and the Alaska Permanent Fund Corporation.
Overall, Denali is focused on developing breakthrough therapies that have the potential to improve the lives of patients with neurodegenerative diseases.
Denali Therapeutics Inc. is a biotechnology firm that is primarily engaged in developing innovative therapies for neurodegenerative diseases. The company has structured its operations around two core segments and has established a diverse array of products and services to meet the needs of patients suffering from these challenging conditions.
Segments
1. Neurodegenerative Diseases:
Denali Therapeutics focuses heavily on neurological conditions that lead to progressive degeneration of the structure and function of the nervous system. This segment includes therapies targeting a range of disorders such as:
- Alzheimers Disease: A progressive brain disorder that leads to memory loss and cognitive decline.
- Parkinsons Disease: A movement disorder characterized by tremors, stiffness, and difficulty with balance and coordination.
- Amyotrophic Lateral Sclerosis (ALS): A fatal neurodegenerative disease affecting motor neurons, leading to loss of muscle control.
- Multiple System Atrophy (MSA): A rare and aggressive neurodegenerative disorder characterized by a combination of Parkinsonian symptoms, autonomic dysfunction, and ataxia.
2. Enzyme Delivery Technology:
This segment centers around Denalis proprietary technology designed to facilitate the transportation of therapeutics across the blood-brain barrier (BBB), a significant challenge in treating brain disorders. This innovative approach can enhance the efficacy of drugs by ensuring they reach their intended targets in the brain more effectively.
Products
Denali Therapeutics has an attractive pipeline that includes several promising product candidates:
1. ATV:
- ATV is Denali’s lead candidate, a small molecule inhibitor specifically formulated to mitigate the aggregation of alpha-synuclein, a protein linked to the pathophysiology of Parkinsons Disease. By targeting this aggregation, ATV aims to slow disease progression and potentially improve patient outcomes.
2. ETV:
- ETV is another significant candidate focused on Alzheimer’s disease and other tauopathies. This small molecule inhibitor is designed to prevent tau protein aggregation, which is critical in the development of neurofibrillary tangles, a hallmark of Alzheimers pathology.
3. LRRK2 Inhibitor:
- This product candidate targets the LRRK2 kinase, whose mutation has been associated with familial and sporadic forms of Parkinsons Disease. The small molecule inhibitor aims to diminish the toxic effects associated with this mutation.
4. FGF20:
- A novel gene therapy product, FGF20 seeks to enhance the production of GABA neurons in the basal ganglia, which are crucial in the motor control circuitry affected in Parkinson’s Disease. By increasing GABA neuron production, this therapy aims to restore balance in neural networks disrupted by neurodegeneration.
5. Enzyme Delivery Technology:
- Alongside its product candidates, Denalis proprietary enzyme delivery technology enables the effective transport of larger therapeutic proteins across the blood-brain barrier, which could revolutionize the treatment landscape for various neurological conditions.
Services
In addition to product development, Denali Therapeutics offers a range of services that support the broader biotechnology community and facilitate the advancement of neurotherapeutics:
1. Drug Discovery and Development Services:
- Denali provides comprehensive services that encompass the entire drug discovery process, from target identification and selection through lead optimization to preclinical development. This ensures that clients are equipped with robust therapeutic candidates before clinical trials.
2. Preclinical and Clinical Development Services:
- The company extends its expertise through consultancy on both preclinical and clinical development phases. This includes clinical trial design, execution, and regulatory strategy, assisting clients in advancing their candidates to market-ready status.
3. Biomarker Discovery Services:
- Denali also conducts biomarker discovery services aimed at identifying and validating biomarkers essential for the early diagnosis and monitoring of neurodegenerative diseases. Identifying these biomarkers can lead to better patient stratification and targeted therapeutic strategies.
Conclusion
In summary, Denali Therapeutics Inc. boasts a multifaceted approach to tackling the complexities of neurodegenerative diseases. With a focused pipeline of innovative product candidates such as ATV, ETV, and others, alongside cutting-edge enzyme delivery technology, Denali is positioned to make significant advancements in the treatment and diagnosis of these challenging conditions. The companys comprehensive service offerings further enhance its role as a leader in biotechnology, reflecting its commitment to addressing the profound unmet medical needs present in the field of neurology.
Segments
1. Neurodegenerative Diseases:
Denali Therapeutics focuses heavily on neurological conditions that lead to progressive degeneration of the structure and function of the nervous system. This segment includes therapies targeting a range of disorders such as:
- Alzheimers Disease: A progressive brain disorder that leads to memory loss and cognitive decline.
- Parkinsons Disease: A movement disorder characterized by tremors, stiffness, and difficulty with balance and coordination.
- Amyotrophic Lateral Sclerosis (ALS): A fatal neurodegenerative disease affecting motor neurons, leading to loss of muscle control.
- Multiple System Atrophy (MSA): A rare and aggressive neurodegenerative disorder characterized by a combination of Parkinsonian symptoms, autonomic dysfunction, and ataxia.
2. Enzyme Delivery Technology:
This segment centers around Denalis proprietary technology designed to facilitate the transportation of therapeutics across the blood-brain barrier (BBB), a significant challenge in treating brain disorders. This innovative approach can enhance the efficacy of drugs by ensuring they reach their intended targets in the brain more effectively.
Products
Denali Therapeutics has an attractive pipeline that includes several promising product candidates:
1. ATV:
- ATV is Denali’s lead candidate, a small molecule inhibitor specifically formulated to mitigate the aggregation of alpha-synuclein, a protein linked to the pathophysiology of Parkinsons Disease. By targeting this aggregation, ATV aims to slow disease progression and potentially improve patient outcomes.
2. ETV:
- ETV is another significant candidate focused on Alzheimer’s disease and other tauopathies. This small molecule inhibitor is designed to prevent tau protein aggregation, which is critical in the development of neurofibrillary tangles, a hallmark of Alzheimers pathology.
3. LRRK2 Inhibitor:
- This product candidate targets the LRRK2 kinase, whose mutation has been associated with familial and sporadic forms of Parkinsons Disease. The small molecule inhibitor aims to diminish the toxic effects associated with this mutation.
4. FGF20:
- A novel gene therapy product, FGF20 seeks to enhance the production of GABA neurons in the basal ganglia, which are crucial in the motor control circuitry affected in Parkinson’s Disease. By increasing GABA neuron production, this therapy aims to restore balance in neural networks disrupted by neurodegeneration.
5. Enzyme Delivery Technology:
- Alongside its product candidates, Denalis proprietary enzyme delivery technology enables the effective transport of larger therapeutic proteins across the blood-brain barrier, which could revolutionize the treatment landscape for various neurological conditions.
Services
In addition to product development, Denali Therapeutics offers a range of services that support the broader biotechnology community and facilitate the advancement of neurotherapeutics:
1. Drug Discovery and Development Services:
- Denali provides comprehensive services that encompass the entire drug discovery process, from target identification and selection through lead optimization to preclinical development. This ensures that clients are equipped with robust therapeutic candidates before clinical trials.
2. Preclinical and Clinical Development Services:
- The company extends its expertise through consultancy on both preclinical and clinical development phases. This includes clinical trial design, execution, and regulatory strategy, assisting clients in advancing their candidates to market-ready status.
3. Biomarker Discovery Services:
- Denali also conducts biomarker discovery services aimed at identifying and validating biomarkers essential for the early diagnosis and monitoring of neurodegenerative diseases. Identifying these biomarkers can lead to better patient stratification and targeted therapeutic strategies.
Conclusion
In summary, Denali Therapeutics Inc. boasts a multifaceted approach to tackling the complexities of neurodegenerative diseases. With a focused pipeline of innovative product candidates such as ATV, ETV, and others, alongside cutting-edge enzyme delivery technology, Denali is positioned to make significant advancements in the treatment and diagnosis of these challenging conditions. The companys comprehensive service offerings further enhance its role as a leader in biotechnology, reflecting its commitment to addressing the profound unmet medical needs present in the field of neurology.